Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LB-100
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Lixte Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Collaboration will support the preclinical studies of the potential benefit of Lixte’s proprietary lead clinical compound, LB-100, in a mouse model of Angelman Syndrome (AS).
Product Name : LB-100
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : LB-100
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Lixte Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration